AMBIZYGO: phase II study of high dose liposomal amphotericin B (AmBisome®) [10 mg/kg/j] efficacy against zygomycosis;AMBIZYGO : étude de phase II de l'efficacité d'une posologie initiale élevée d'amphotéricine B liposomale (AmBisome®) [10 mg/kg/j] dans le traitement des zygomycoses

Medecine et Maladies Infectieuses

Volumn 38, Issue SUPPL. 2, 2008, Pages

  Lanternier, F ^a   Lortholary, O ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Liposomal amphotericin B; Zygomycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FLUCYTOSINE; POSACONAZOLE; VORICONAZOLE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; MUCORMYCOSIS; PHASE 2 CLINICAL TRIAL; SHORT SURVEY; TREATMENT RESPONSE;

AMPHOTERICIN B; FEMALE; HUMANS; MALE; PATIENT SELECTION; TREATMENT OUTCOME; ZYGOMYCOSIS;

EID: 45849151732     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/S0399-077X(08)73003-8     Document Type: Short Survey

References (0)